Chester County News and Community Website
WILMINGTON, DE — NiKang Therapeutics Inc. announced it has completed dosing in the first patient cohort of its Phase 1 dose-escalation study evaluating NKT5097, an oral small molecule designed to …
NiKang Therapeutics Advances First-in-Class CDK2/4 Dual Degrader in Phase 1 Study Read More
CHICAGO, IL & EXTON, PA — SimBioSys® and Ricoh 3D for Healthcare, LLC, a subsidiary of Ricoh USA, have entered into a distribution agreement to expand access to TumorSight™ Viz, …
SimBioSys and Ricoh Partner to Expand Access to 3D Breast Cancer Surgical Planning Tool Read More
WILMINGTON, DE — A groundbreaking study by ChristianaCare’s Cawley Center for Translational Cancer Research has identified key factors behind Delaware’s elevated rates of advanced breast cancer and laid the groundwork for …
New ChristianaCare Study Pinpoints Causes Behind Delaware’s Breast Cancer Hotspots Read More
WILMINGTON, DE — The Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab significantly improves progression-free survival (PFS) for patients with HER2-positive metastatic …
ENHERTU plus Pertuzumab Shows Significant Progress in First-Line Treatment for HER2-Positive Breast Cancer Read More WILMINGTON, DE — Groundbreaking results from AstraZeneca’s Phase III SERENA-6 trial reveal a significant leap forward in the treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer. The trial demonstrated …
AstraZeneca’s SERENA-6 Trial Marks Breakthrough in Breast Cancer Treatment Read More
WILMINGTON, DE — Farmers of Salem, a regional mutual insurance company specializing in coverage for homes and businesses, is celebrating Loraine Lester, AVP of Product & Underwriting Development, for her …
Farmers of Salem Celebrates Loraine Lester’s Contributions to Community and Career Read More WILMINGTON, DE — Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when followed by paclitaxel, trastuzumab, and pertuzumab (THP), significantly improved pathologic complete response (pCR) …
ENHERTU Shows Promise in Early-Stage HER2-Positive Breast Cancer Read More WILMINGTON, DE — High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in combination with pertuzumab, significantly improves progression-free survival (PFS) compared to the current 1st-line …
ENHERTU Combination Shows Promising Results in HER2-Positive Metastatic Breast Cancer Trial Read More
WEST READING, PA — Tower Health is urging women to prioritize their breast health this March through its “Slam Dunk Mammo Screening” campaign. The initiative, running throughout the month, encourages women …
Tower Health Launches “Slam Dunk Mammo Screening” Campaign Read More
MALVERN, PA — Galera Therapeutics, Inc. (OTC: GRTX) has announced its acquisition of Nova Pharmaceuticals, Inc., a biotechnology company focused on treating resistant forms of breast cancer, including metaplastic and …
Galera Therapeutics Acquires Nova Pharmaceuticals to Advance Breast Cancer Treatment Read More